Wall Street ends higher with help from tech, energy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
bluebird bio (BLUE) Prices 3.24M Share Common Offering at $185/Sh
December 13, 2017 5:44 AM ESTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share,... More
UPDATE: Celgene (CELG) PT Raised to $110 at Wells Fargo on 'bb2121 and Next-Gen CelMods' Updates at ASH Meetings
December 12, 2017 8:11 AM EST(Updated - December 12, 2017 8:12 AM EST)
Wells Fargo raised its price target on Celgene (NASDAQ: CELG) to $110.00 (from $101.00) while maintaining a Market Perform rating, following meetings at the American Society of Hematology.
Analyst Birchenough notes a positive outlook on the shares, following the... More
bluebird bio (BLUE) PT Raised to $225 at Wedbush
December 11, 2017 1:29 PM ESTWedbush raised its price target on bluebird bio (NASDAQ: BLUE) to $225.00 (from $174.00) while maintaining an Outperform rating after the company reported positive data in all three reported clinical programs.
"Early Group C data for sickle cell disease at 30 days were encouraging, and five... More
bluebird bio (BLUE) PT Raised to $223 at SunTrust Robinson Humphrey
December 11, 2017 8:53 AM ESTSunTrust Robinson Humphrey analyst Edward Nash raised his price target on bluebird bio (NASDAQ: BLUE) to $223.00 (from $163.00) while maintaining a Buy rating.
Nash cited the "robust durability data across all programs" presented at ASH.
"We believe the new process... More
